Last reviewed · How we verify
Hydrochlorothiazide 12.5mg
At a glance
| Generic name | Hydrochlorothiazide 12.5mg |
|---|---|
| Also known as | HCTZ, mild antihypertensive comparator, HCT |
| Sponsor | University of Kansas Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control (PHASE3)
- Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) (PHASE3)
- Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction (EARLY_PHASE1)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- The Role of Skin Sodium Accumulation in Chronic Kidney Disease (NA)
- Mitigating the Pro-inflammatory Phenotype of Obesity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrochlorothiazide 12.5mg CI brief — competitive landscape report
- Hydrochlorothiazide 12.5mg updates RSS · CI watch RSS
- University of Kansas Medical Center portfolio CI